Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3 results

Filters applied: . Clear all
Page 1
Safety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043-02): an open-label, dose-expansion, randomised, controlled, phase 1b/2a trial.
Heinrich N, de Jager V, Dreisbach J, Gross-Demel P, Schultz S, Gerbach S, Kloss F, Dawson R, Narunsky K, Matt L, Wildner L, McHugh TD, Fuhr U, Aldana BH, Mouhdad C, Brake LT, Boeree MJ, Aarnoutse RE, Svensson EM, Gong X, P J Phillips P, Diacon AH, Hoelscher M; PanACEA-TB consortium. Heinrich N, et al. Among authors: gross demel p. Lancet Microbe. 2025 Feb;6(2):100952. doi: 10.1016/j.lanmic.2024.07.015. Epub 2025 Jan 7. Lancet Microbe. 2025. PMID: 39793592 Free article. Clinical Trial.
Population pharmacokinetics and exposure-response relationship of the antituberculosis drug BTZ-043.
Koele SE, Heinrich N, De Jager VR, Dreisbach J, Phillips PPJ, Gross-Demel P, Dawson R, Narunsky K, Wildner LM, Mchugh TD, Te Brake LHM, Diacon AH, Aarnoutse RE, Hoelscher M, Svensson EM. Koele SE, et al. Among authors: gross demel p. J Antimicrob Chemother. 2025 May 2;80(5):1315-1323. doi: 10.1093/jac/dkaf076. J Antimicrob Chemother. 2025. PMID: 40155063 Free PMC article. Clinical Trial.
Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB.
Koele SE, Stoycheva K, Mtweve C, Manyama C, Mpagama S, Mhimbira F, Wallis R, Ntinginya NE, Liyoyo A, Huglin B, Minja LT, Wagnerberger L, Zumba T, Noreña I, Peter DD, Beattie T, Makkan H, Sloan DJ, Te Brake L, Aarnoutse RE, McHugh TD, Wildner L, Schildkraut J, Aldana BH, Phillips PPJ, Hoelscher M, Svensson EM, Heinrich N; PanACEA consortium. Koele SE, et al. J Antimicrob Chemother. 2025 Aug 1;80(8):2305-2313. doi: 10.1093/jac/dkaf210. J Antimicrob Chemother. 2025. PMID: 40613338 Free PMC article. Clinical Trial.